Cochrane · systematic review · CD002219

Ivermectin for onchocercal eye disease (river blindness)

Ejere, HOD, Schwartz, E, Wormald, R, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library

Eyes and Vision2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 35.7%Very low 1 · 7.1%Low 4 · 28.6%Moderate 3 · 21.4%High 1 · 7.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Ivermectin to prevent and treat onchocercal eye disease in people infected with O.volvulus

Population: people infected with O.volvulus
7 questions
OutcomeEffectEvidenceStatus / GRADE
Visual impairment
no estimate extracted2 studies · 354 participantsUngraded
Visual field loss
no estimate extracted0 studies · 0 participantsUngraded
Punctate keratitis
no estimate extracted0 studies · 2 participantsUngraded
Sclerosing keratitis
RR 0.06 [0, 1.23]1 study · 39 participantsLow
Downgraded: imprecision, indirectness
Iridocyclitis
no estimate extracted0 studies · 2 participantsUngraded
Chorioretinitis
RR 0.02 [0, 0.32]1 study · 200 participantsModerate
Downgraded: indirectness
Optic nerve disease
no estimate extracted2 studies · 354 participantsUngraded

Ivermectin to prevent and treat onchocercal eye disease in people living in communities affected by O.volvulus

Population: people living in communities affected by O.volvulus
7 questions
OutcomeEffectEvidenceStatus / GRADE
Visual impairment
RR 1.08 [0.33, 3.5]1 study · 485 participantsVery low
Downgraded: risk of bias, imprecision, indirectness
Visual field loss
RR 0.6 [0.41, 0.89]1 study · 636 participantsHigh
Punctate keratitis
RR 0.33 [0.22, 0.49]1 study · 551 participantsModerate
Downgraded: risk of bias
Sclerosing keratitis
RR 0.74 [0.52, 1.06]1 study · 560 participantsLow
Downgraded: risk of bias, imprecision
Iridocyclitis
RR 0.62 [0.43, 0.9]1 study · 554 participantsModerate
Downgraded: risk of bias
Chorioretinitis
RR 1.75 [0.91, 3.37]1 study · 528 participantsLow
Downgraded: risk of bias, imprecision
Optic nerve disease
RR 0.78 [0.57, 1.06]2 studies · 3577 participantsLow
Downgraded: risk of bias, inconsistency